neutralizing

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody expressed in CHO cells, effectively competes with the virus Spike protein for binding to the CD26 receptor, thereby inhibiting viral invasion into host cells.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1 that specifically targets the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD), effectively neutralizing the virus by blocking its ability to bind to receptors [1].

Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.

Motavizumab (MEDI-524) is a monoclonal antibody neutralizing respiratory syncytial virus (RSV), altering local and systemic cytokine responses in mouse models, used in the study of RSV infection.

Tabalumab (LY2127399), a humanized monoclonal antibody (IgG4 type) targeting B-cell activating factor (BAFF), exhibits neutralizing activity against both membrane-bound and soluble BAFF. This compound is relevant for research into autoimmune diseases, including rheumatoid arthritis, renal failure, and systemic lupus erythematosus [1].

Namilumab (AMG203), a human IgG1 monoclonal antibody, exhibits high affinity binding to the GM-CSF ligand, effectively neutralizing GM-CSF. It has potential application in researching rheumatoid arthritis [1].

Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML).

Suvizumab (KD-247), a neutralizing antibody against HIV-1, effectively neutralizes strains HIV-1 MN, HIV-1 SF2, and HIV-1 89.6, exhibiting IC50 values of 0.1 µg mL, 1.0 µg mL, and 0.2 µg mL, respectively. It demonstrates a significant reduction in viral load, indicating its efficacy in preventing HIV infection. Suvizumab is also well-tolerated, further supporting its potential as a preventative treatment for HIV [1] [2].

Felvizumab (SB 209763), a humanized IgG1κ monoclonal antibody, targets specific neutralizing epitopes on the F glycoprotein of Respiratory Syncytial Virus (RSV) [1] [2].

Fiztasovimab (NPC-21; EV2038), a fully human IgG1λ monoclonal antibody (mAb), targets human cytomegalovirus (hCMV). It exerts its neutralizing activity through binding to the antigenic domain 1 of glycoprotein B on the hCMV envelope, effectively inhibiting cell-to-cell transmission of hCMV [1].

Libivirumab (17.1.41), a humanized monoclonal antibody targeting hepatitis B virus (HBV), demonstrates neutralizing activity with half maximal inhibitory concentrations (IC50) of 35 ng mL for HBsAg and 130 ng mL for HBeAg, respectively [1].

Lomtegovimab (BI 767551), a humanized monoclonal antibody targeting the SARS-CoV-2 spike glycoprotein, exhibits antiviral efficacy by binding to and neutralizing the virus. This compound holds potential for COVID-19 research [1] [2].

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].

Elipovimab, a potent and broadly neutralizing antibody against HIV-1, targets and eliminates HIV-infected cells [1].

Rimteravimab (XVR011) is a bivalent VHH-Fc antibody that targets the disease caused by SARS-CoV-2, exhibiting potent neutralizing activity, high stability, broad coverage, and silenced Fc effector functions [1].

Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA.

Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing monoclonal antibody that specifically binds to IFNAR1, blocking its signaling both in vitro and in vivo. It is of the Mouse IgG1 kappa isotype, with a corresponding isotype control [1] [2].

Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.

Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1 PD-L1 relapsed refractory metastatic solid tumors [1].

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed as a decoy or scavenger to target Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE) research [1].

Marstacimab (PF-06741086) is a neutralizing antibody that binds to and inhibits inhibitors of the human tissue factor pathway. Marstacimab is an anti-tissue factor pathway inhibitor used in the study of hemophilia.

S2H97 is a neutralizing antibody that broadly protects against viruses such as C pneumoniae and SARS under clade B of coronavirus B. RSM01 is a fully human monoclonal antibody against RSV.